

OMALIZUMAB BENEFIT CRITERIA TO CHANGE FOR TEXAS MEDICAID DECEMBER 1, 2016

The following information was posted to the TMHP website on October 26.

Effective for dates of service on or after December 1, 2016, the additional omalizumab documentation requirements will change for Texas Medicaid.

The required total IgE level will change from greater than 30 IU/ml but less than 700 IU/ml within the past 12 months to the following:

- Greater than 30 IU/ml but less than 1300 IU/ml within the past 12 months

In the fee-for-service policy, documentation that the client meets this criterion must be included with the prior authorization request. Refer to the "Medical and Nursing Specialists, Physicians, and Physician Assistant's Handbook" in the Texas Medicaid Provider Procedures Manual for the complete medical necessity documentation and criteria required for fee-for-service prior authorization requests for omalizumab.